---
title: Digital Adherence Program_Xeljanz
description: General education and support on treatment knowledge, medication use, and precautions for use, adverse effects and interactions with other medicines.
---

[![ma_logo_horizontal_full_white_bg](https://www.mymedadvisor.com/hubfs/ma_logo_horizontal_full_white_bg.svg "ma_logo_horizontal_full_white_bg")](http://mymedadvisor.com)

# Xeljanz**® **(tofacitinib citrate)

Digital Adherence Program

Program overview

This sponsored program aims to provide education and support to patients prescribed Xeljanz for the treatment of ulcerative colitis.

Patients will receive a series of 12 messages over 9 months aimed at improving their quality use of medicines, medication adherence and treatment outcomes.

When?

This program was launched in April 2022.

For which patients?

Messages will be delivered via the app to patients currently prescribed Xeljanz for the treatment of ulcerative colitis. 

[Click here to view a sample of the messages](https://www.mymedadvisor.com/hubfs/Xeljanz%20DAP_messages.pdf?hsLang=en)

![Xeljanz-1](https://www.mymedadvisor.com/hs-fs/hubfs/Xeljanz-1.png?width=251&name=Xeljanz-1.png "Xeljanz-1")

© 2026 MedAdvisor International Pty Ltd